• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.高剂量氨苄西林-舒巴坦组合在中空纤维感染模型中对抗多粘菌素耐药鲍曼不动杆菌
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01268-16. Print 2017 Mar.
2
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Using Checkerboard Information.舒巴坦/美罗培南/多黏菌素 B 联合用药对极度耐药的药效学影响。采用棋盘信息法。
Microb Drug Resist. 2019 Nov;25(9):1266-1274. doi: 10.1089/mdr.2018.0283. Epub 2019 Jun 19.
3
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.耐多粘菌素、耐碳青霉烯类鲍曼不动杆菌可被三种单独无活性的药物联合使用所根除。
J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.
4
In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.氨苄西林/舒巴坦、多利培南和替加环素单独及联合用于模拟人体暴露时对多重耐药鲍曼不动杆菌的体外药效学研究。
J Antimicrob Chemother. 2013 Oct;68(10):2296-304. doi: 10.1093/jac/dkt197. Epub 2013 May 24.
5
Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.非多黏菌素类联合用药作为治疗碳青霉烯类耐药鲍曼不动杆菌感染的潜在替代品。
Int J Antimicrob Agents. 2020 Oct;56(4):106115. doi: 10.1016/j.ijantimicag.2020.106115. Epub 2020 Jul 25.
6
A carbapenem-resistant Acinetobacter baumannii outbreak associated with a polymyxin shortage during the COVID pandemic: an in vitro and biofilm analysis of synergy between meropenem, gentamicin and sulbactam.耐碳青霉烯鲍曼不动杆菌爆发与 COVID 大流行期间多粘菌素短缺有关：美罗培南、庆大霉素和舒巴坦之间协同作用的体外和生物膜分析。
J Antimicrob Chemother. 2022 May 29;77(6):1676-1684. doi: 10.1093/jac/dkac102.
7
New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.新型多粘菌素B给药策略助力对抗产KPC-2肺炎克雷伯菌的“老盟友”
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02023-16. Print 2017 Apr.
8
[Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].[用于评估棋盘协同试验的不同解释方法会影响结果吗？]
Mikrobiyol Bul. 2012 Jul;46(3):410-20.
9
Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.多黏菌素 E 联合或不联合美满霉素对不同米诺环素敏感性的碳青霉烯类药物耐药鲍曼不动杆菌的活性。
Microbiol Spectr. 2022 Jun 29;10(3):e0054222. doi: 10.1128/spectrum.00542-22. Epub 2022 Jun 1.
10
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].[耐碳青霉烯类鲍曼不动杆菌的耐药机制及体外联合用药的应用]
Zhonghua Shao Shang Za Zhi. 2014 Apr;30(2):166-70.

引用本文的文献

1
High Prevalence of Virulence and Genes Encoding Carbapenemases Among Isolates from Hospitalised Patients in Three Regions of Poland.波兰三个地区住院患者分离株中耐药性及碳青霉烯酶编码基因的高流行率
Pathogens. 2025 Jul 24;14(8):731. doi: 10.3390/pathogens14080731.
2
activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant .舒巴坦与其他抗菌药物联合使用对广泛耐药菌的活性。
Microbiol Spectr. 2025 Sep 2;13(9):e0137925. doi: 10.1128/spectrum.01379-25. Epub 2025 Aug 12.
3
Emergence of carbapenem-resistant clonal complex 2 in multiple hospitals in São Paulo state, Brazil.巴西圣保罗州多家医院中耐碳青霉烯类的克隆复合体2的出现。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0186524. doi: 10.1128/aac.01865-24. Epub 2025 Jul 23.
4
Combatting mobile colistin-resistant (MCR), metallo-β-lactamase (MBL)-producing persisters.对抗耐黏菌素移动性（MCR）、产金属β-内酰胺酶（MBL）的持留菌。
JAC Antimicrob Resist. 2025 Jul 22;7(4):dlaf132. doi: 10.1093/jacamr/dlaf132. eCollection 2025 Aug.
5
Biomarker-Driven Pharmacokinetics and Efficacy of Polymyxin B in Critically Ill Patients with XDR-GN Pneumonia.生物标志物驱动的多黏菌素B在XDR-GN肺炎重症患者中的药代动力学及疗效
Pharmaceuticals (Basel). 2025 Apr 17;18(4):586. doi: 10.3390/ph18040586.
6
Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?以冗余对抗耐药性：治疗抗微生物药物耐药感染的前进之路？
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0012125. doi: 10.1128/aac.00121-25. Epub 2025 Mar 14.
7
Carbapenem-resistant and Ventilator-associated Pneumonia; Epidemiology, Risk Factors, and Current Therapeutic Approaches.耐碳青霉烯类与呼吸机相关性肺炎：流行病学、危险因素及当前治疗方法
J Res Pharm Pract. 2024 Dec 23;13(2):33-40. doi: 10.4103/jrpp.jrpp_50_24. eCollection 2024 Apr-Jun.
8
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.耐碳青霉烯鲍曼不动杆菌感染的治疗方法
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
9
Maximally precise combinations to overcome metallo-β-lactamase-producing .最大限度精确组合以克服产金属-β-内酰胺酶的。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0077024. doi: 10.1128/aac.00770-24. Epub 2024 Sep 17.
10
Treatment of infections caused by carbapenem-resistant .治疗耐碳青霉烯类抗生素的感染。
Front Cell Infect Microbiol. 2024 Jul 18;14:1395260. doi: 10.3389/fcimb.2024.1395260. eCollection 2024.

本文引用的文献

1
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.美罗培南与多粘菌素B的高强度联合应用：克服鲍曼不动杆菌碳青霉烯类耐药性的新策略。
J Antimicrob Chemother. 2017 Jan;72(1):153-165. doi: 10.1093/jac/dkw355. Epub 2016 Sep 15.
2
Agents of Last Resort: Polymyxin Resistance.终极手段：多粘菌素耐药性
Infect Dis Clin North Am. 2016 Jun;30(2):391-414. doi: 10.1016/j.idc.2016.02.005.
3
Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.多粘菌素B的矛盾效应：高药物暴露会增强鲍曼不动杆菌的耐药性
Antimicrob Agents Chemother. 2016 Jun 20;60(7):3913-20. doi: 10.1128/AAC.02831-15. Print 2016 Jul.
4
Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.万古霉素中介耐药性的序贯演变改变金黄色葡萄球菌的毒力：万古霉素暴露的药代动力学/药效学靶点
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1584-91. doi: 10.1128/AAC.02657-15.
5
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.耐黏菌素鲍曼不动杆菌：超越碳青霉烯类耐药性
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.
6
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.鲍曼不动杆菌中舒巴坦抗菌活性及耐药决定因素的分子机制
Antimicrob Agents Chemother. 2015 Mar;59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5.
7
Detection of pan drug-resistant Acinetobacter baumannii in Germany.德国泛耐药鲍曼不动杆菌的检测
J Antimicrob Chemother. 2014 Sep;69(9):2578-9. doi: 10.1093/jac/dku170. Epub 2014 May 15.
8
Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.体外和小鼠大腿及肺部感染模型中评估舒巴坦对鲍曼不动杆菌的药代动力学/药效学。
Int J Antimicrob Agents. 2014 Jun;43(6):547-52. doi: 10.1016/j.ijantimicag.2014.02.012. Epub 2014 Mar 30.
9
Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media.用于检测细菌生长培养基中多粘菌素B的液相色谱-质谱分析法的开发与验证
J Pharm Biomed Anal. 2014 Apr;92:177-82. doi: 10.1016/j.jpba.2014.01.015. Epub 2014 Jan 24.
10
Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.系统评价和体外协同作用的多粘菌素和碳青霉烯类抗生素的荟萃分析。
Antimicrob Agents Chemother. 2013 Oct;57(10):5104-11. doi: 10.1128/AAC.01230-13. Epub 2013 Aug 5.

高剂量氨苄西林-舒巴坦组合在中空纤维感染模型中对抗多粘菌素耐药鲍曼不动杆菌

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

作者信息

Lenhard Justin R, Smith Nicholas M, Bulman Zackery P, Tao Xun, Thamlikitkul Visanu, Shin Beom S, Nation Roger L, Li Jian, Bulitta Jürgen B, Tsuji Brian T

机构信息

Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, Buffalo, New York, USA.

School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, New York, USA.

出版信息

Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01268-16. Print 2017 Mar.

DOI:10.1128/AAC.01268-16
PMID:28052852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5328540/
Abstract

is emerging with resistance to polymyxins. In 24-h time-kill experiments, high-dose ampicillin-sulbactam in combination with meropenem and polymyxin B achieved additivity or synergy against 10 CFU/ml of two clinical isolates resistant to all three drugs (maximum reductions, 1.6 and 3.1 logs). In a 14-day hollow-fiber infection model, high-dose ampicillin-sulbactam (8/4 g every 8 h, respectively) in combination with meropenem (2 g every 8 h) and polymyxin B (1.43 mg/kg of body weight every 12 h with loading dose) resulted in rapid (96 h) eradication of .

摘要

对多粘菌素产生耐药性的情况正在出现。在24小时杀菌试验中，高剂量氨苄西林-舒巴坦联合美罗培南和多粘菌素B对每毫升10菌落形成单位的两种对所有三种药物耐药的临床分离株具有相加或协同作用（最大降低量分别为1.6和3.1个对数）。在14天的中空纤维感染模型中，高剂量氨苄西林-舒巴坦（分别为每8小时8/4克）联合美罗培南（每8小时2克）和多粘菌素B（每12小时1.43毫克/千克体重，负荷剂量）导致迅速（96小时）清除……